AU6036690A - Human monoclonal antibodies to hiv-1mn gp 120 - Google Patents

Human monoclonal antibodies to hiv-1mn gp 120

Info

Publication number
AU6036690A
AU6036690A AU60366/90A AU6036690A AU6036690A AU 6036690 A AU6036690 A AU 6036690A AU 60366/90 A AU60366/90 A AU 60366/90A AU 6036690 A AU6036690 A AU 6036690A AU 6036690 A AU6036690 A AU 6036690A
Authority
AU
Australia
Prior art keywords
hiv
monoclonal antibodies
human monoclonal
human
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU60366/90A
Other languages
English (en)
Inventor
Helen F. Carson
James R. Rusche
Charles F. Scott Jr.
Sandra Silver
Mary E. White-Scharf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WHITE SCHARF MARY E
Original Assignee
WHITE SCHARF MARY E
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WHITE SCHARF MARY E filed Critical WHITE SCHARF MARY E
Publication of AU6036690A publication Critical patent/AU6036690A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
AU60366/90A 1989-06-05 1990-06-05 Human monoclonal antibodies to hiv-1mn gp 120 Abandoned AU6036690A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36154189A 1989-06-05 1989-06-05
US361541 1989-06-05
US43128189A 1989-11-03 1989-11-03
US431281 1989-11-03

Publications (1)

Publication Number Publication Date
AU6036690A true AU6036690A (en) 1991-01-07

Family

ID=27001330

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60366/90A Abandoned AU6036690A (en) 1989-06-05 1990-06-05 Human monoclonal antibodies to hiv-1mn gp 120

Country Status (7)

Country Link
EP (1) EP0478689A4 (fr)
JP (1) JPH05506561A (fr)
AU (1) AU6036690A (fr)
CA (1) CA2058630A1 (fr)
IL (1) IL94624A0 (fr)
PT (1) PT94276A (fr)
WO (1) WO1990015078A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712373A (en) * 1990-07-02 1998-01-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute HIV monoclonal antibody specific for the HTLV-IIImn gp120 envelope glycoprotein
JP2989862B2 (ja) * 1990-07-02 1999-12-13 財団法人化学及血清療法研究所 モノクローナル抗体
AU9072991A (en) * 1990-10-26 1992-05-26 Public Health Research Institute Of The City Of New York, Inc., The Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
IT1244529B (it) * 1991-01-30 1994-07-15 Ist Superiore Sanita Peptidi sintetici atti a potenziare l'infettivita' del virus hiv-1
WO1994004574A1 (fr) * 1991-08-22 1994-03-03 Nissin Shokuhin Kabushiki Kaisha Immunotherapie du vih
WO1993004090A1 (fr) * 1991-08-22 1993-03-04 Nissin Shokuhin Kabushiki Kaisha Immunotherapie du vih
HUT70461A (en) * 1992-04-01 1995-10-30 Merck Anc Co Inc Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv invention
PT728015E (pt) 1992-06-18 2006-07-31 Creagen Inc Antigenes polipeptidicos combinatoriais
EP0588750A3 (fr) * 1992-08-05 1995-01-11 Cigb Procédé pour la production de polypeptides recombinants contenant des épitopes dérivées d'isolées d'HIV différentes, leur utilisations comme immunigènes et pour la détection d'anticorps contre le HIV.
US6114143A (en) * 1993-03-11 2000-09-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-HIV monoclonal antibody
US5618922A (en) * 1994-07-25 1997-04-08 Nissin Shokuhin Kabushiki Kaisha NM03 antibody materials and methods
US8332159B2 (en) 2003-02-20 2012-12-11 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for enhancing efficacy of preparation of monoclonal antibody

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755457A (en) * 1985-02-05 1988-07-05 Robert Guroff Marjorie Method for detecting HTLV-III neutralizing antibodies in sera
ATE122237T1 (de) * 1987-05-29 1995-05-15 Tanox Biosystems Inc Hiv-1 neutralisierende monoklonale antikörper.
EP0339504A3 (fr) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Virus d'immunodéficience humaine (HIV) peptide env-codé capable de provoquer les anticorps inhibiteurs du HIV dans les mammifères
JPH04502760A (ja) * 1988-10-03 1992-05-21 レプリゲン・コーポレーション エイズの診断，予防および治療に有効な新規ｈｉｖ蛋白質およびペプチド
WO1991006575A1 (fr) * 1989-11-03 1991-05-16 Repligen Corporation Anticorps monoclonal humain specifique du vih-1

Also Published As

Publication number Publication date
IL94624A0 (en) 1991-04-15
PT94276A (pt) 1991-02-08
CA2058630A1 (fr) 1990-12-06
EP0478689A4 (en) 1993-06-16
EP0478689A1 (fr) 1992-04-08
WO1990015078A1 (fr) 1990-12-13
JPH05506561A (ja) 1993-09-30

Similar Documents

Publication Publication Date Title
AU5267190A (en) Modified antibodies
AU1480388A (en) Altered antibodies
AU2782789A (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
GB2186592B (en) Cross-protective human monoclonal antibody compositions
AU6036690A (en) Human monoclonal antibodies to hiv-1mn gp 120
AU3330689A (en) Monoclonal antibodies
EP0285511A3 (en) Monoclonal antibodies and their uses
AU5435990A (en) Monoclonal antibodies to human glutathione s transferase pi
AU8944291A (en) Immunoassay for the determination of anti-hiv antibodies in human samples
AU2383288A (en) Human anti-rh(d) monoclonal antibodies
AU7649187A (en) Preparation of monoclonal antibodies
AU680836B2 (en) Human monoclonal antibodies to human immunodeficiency virus
AU618720B2 (en) Monoclonal antibodies
GB8927389D0 (en) Monoclonal antibodies
AU2521288A (en) Human anti-rh(d) monoclonal antibodies
AU2546088A (en) Human monoclonal antibody against aspergilli
AU7862291A (en) Modified antibodies
AU5217890A (en) Monoclonal antibodies in vaccine formulations
AU6964891A (en) Novel monoclonal antibody against human platelets
AU2389588A (en) Human anti-rh(d) monoclonal antibodies
AU3698789A (en) Antibodies
ZA904305B (en) Human monoclonal antibodies to hiv-1 mn gp 120
AU6861987A (en) Cross-protective human monoclonal antibody compositions
IE891095L (en) Human monoclonal antibodies
AU612122C (en) Monoclonal antibodies